Inhibition of Immune Complex-mediated Activation of Complement. Effects of Agents Modulating Activation Of, and the Activated C1 Complex

Overview

Journal Inflammation

Specialties Allergy & Immunology
Pathology

Date 1980 Mar 1

PMID 6967051

Citations 3

Authors

D S Fletcher

T Y Lin

Affiliations

Soon will be listed here.

Abstract

Several known chemical compounds were shown to selectively inhibit the interaction between immune aggregates and C1q, the activation of C1r-C1s complex by immune aggregate-bound C1q, and the esterolytic activity of the activated C1s, C1s. These reactions are relevant to the functions of the first complement component, C1, and its activation induced by immune complexes. The effects of these inhibitors on tissue injury mediated by immune complex-induced complement activation, such as immune hemolysis, passive cutaneous anaphylaxis, and experimental glomerulonephritis were examined. The results suggest an approximate correlation between the activity shown on the molecular level and that obtained in vivo. One such compound, suramin, was shown to be an effective inhibitor of PCA and the proteinuria manifestation of EGN while not affecting antibody fixation to tissue or histamine-mediated skin reaction. These results suggest that effective suppression of the initial steps of complement activation may be of value of controlling immune complex-mediated tissue injuries in disease.

Citing Articles

The bumpy road of purinergic inhibitors to clinical application in immune-mediated diseases.

Wyss M, Heuer C, Herwerth M Neural Regen Res. 2023; 19(6):1206-1211.

PMID: 37905866 PMC: 11467927. DOI: 10.4103/1673-5374.386405.

Acute paw oedema formation induced by ATP: re-evaluation of the mechanisms involved.

Ziganshina L, Ziganshin A, Hoyle C, Burnstock G Inflamm Res. 1996; 45(2):96-102.

PMID: 8907591 DOI: 10.1007/BF02265122.

Pharmacologic characterization of immune complex induced bronchoconstriction in guinea pigs.

MIELENS Z, Ferguson E, FERRARI R Agents Actions. 1981; 11(6-7):673-8.

PMID: 6462038 DOI: 10.1007/BF01978788.

References

Furuichi K, Kato M, Nakamura T, Koyama J . Further evidence for preferential production of IgG2 anti-DNP antibody in guinea pigs immunized with DNP-Escherichia coli. Immunochemistry. 1976; 13(5):455-9. DOI: 10.1016/0019-2791(76)90383-9. View

Takada Y, Arimoto Y, MINEDA H, Takada A . Inhibition of the classical and alternative pathways by amino acids and their derivatives. Immunology. 1978; 34(3):509-15. PMC: 1457603. View

LEVY L, Lepow I . Assay and properties of serum inhibitor of C'l-esterase. Proc Soc Exp Biol Med. 1959; 101:608-11. DOI: 10.3181/00379727-101-25034. View

Soter N, Austen K, Gigli I . Inhibition by epsilon-aminocaproic acid of the activation of the first component of the complement system. J Immunol. 1975; 114(3):928-32. View

Conradie J, Volanakis J, Stroud R . Evidence for a serum inhibitor of Clq. Immunochemistry. 1975; 12(12):967-71. DOI: 10.1016/0019-2791(75)90260-8. View

Agnello V, Koffler D, Eisenberg J, Winchester R, Kundel H . C1g precipitins in the sera of patients with systemic lupus erythematosus and other hypocomplementemic states: characterization of high and low molecular weight types. J Exp Med. 1971; 134(3 Pt 2):228s-241s. View

WILLS E, WORMALL A . Studies on suramin; the action of the drug on some enzymes. Biochem J. 1950; 47(2):158-70. PMC: 1275183. DOI: 10.1042/bj0470158. View

Zvaifler N . The immunopathology of joint inflammation in rheumatoid arthritis. Adv Immunol. 1973; 16(0):265-336. DOI: 10.1016/s0065-2776(08)60299-0. View

Asghar S, Pondman K, Cormane R . Inhibition of C1r, C1s and generation of C1s by amidino compounds. Biochim Biophys Acta. 2009; 317(2):539-48. DOI: 10.1016/0005-2795(73)90247-x. View

10.

Andrews J, Rosen F, Silverberg S, Cory M, Schneeberger E, Bing D . Inhibition of C1s-induced vascular leakage in guinea pigs by substituted benzamidine and pyridinium compounds. J Immunol. 1977; 118(2):466-71. View

11.

Winchester R, Agnello V, KUNKEL H . Gamma globulin complexes in synovial fluids of patients with rheumatoid arthritis. Partial characterization and relationship to lowered complement levels. Clin Exp Immunol. 1970; 6(5):689-706. PMC: 1712723. View

12.

Chapuis R, ISLIKER H, Assimeh S . Studies on the precursor form of the first component of complement--I. Isolation of the proenzyme forms of Clr and Cls. Immunochemistry. 1977; 14(5):313-7. DOI: 10.1016/0019-2791(77)90229-4. View

13.

Brackertz D, Kueppers F . A one year's follow up of treatment of hereditary angioneurotic edema (HAE) with suramin. Allergol Immunopathol (Madr). 1974; 2(3):163-8. View

14.

Gigli I, Porter R, Sim R . The unactivated form of the first component of human complement, C1. Biochem J. 1976; 157(3):541-8. PMC: 1163895. DOI: 10.1042/bj1570541. View

15.

Hughes-Jones N, Gardner B . The reaction between the complement subcomponent C1q, IgG complexes and polyionic molecules. Immunology. 1978; 34(3):459-63. PMC: 1457604. View

16.

Lin T, Fletcher D . Interaction of human Clq with insoluble immunoglobulin aggregates. Immunochemistry. 1978; 15(2):107-17. DOI: 10.1016/0161-5890(78)90050-0. View

17.

Fong J, GOOD R . Suramin--a potent reversible and competitive inhibitor of complement systems. Clin Exp Immunol. 1972; 10(1):127-38. PMC: 1713099. View

18.

Augener W, Grey H, Cooper N, MULLER-EBERHARD H . The reaction of monomeric and aggregated immunoglobulins with C1. Immunochemistry. 1971; 8(11):1011-20. DOI: 10.1016/0019-2791(71)90489-7. View

19.

UNANUE E, Dixon F . EXPERIMENTAL GLOMERULONEPHRITIS. IV. PARTICIPATION OF COMPLEMENT IN NEPHROTOXIC NEPHRITIS. J Exp Med. 1964; 119:965-82. PMC: 2137751. DOI: 10.1084/jem.119.6.965. View

20.

Weber K, Osborn M . The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem. 1969; 244(16):4406-12. View